| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Waldencast plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.36 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$5.00 |
| Beta | 0 |
| 1 Month Change | -17.03% |
| 3 Month Change | -29.57% |
| 1 Year Change | -41.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.48% |
Recent News & Updates
Shareholder Returns
| WALD | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -0.6% | 5.4% | 1.2% |
| 1Y | -41.7% | -25.4% | 24.7% |
Return vs Industry: WALD underperformed the US Personal Products industry which returned -32.6% over the past year.
Return vs Market: WALD underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| WALD volatility | |
|---|---|
| WALD Average Weekly Movement | 12.2% |
| Personal Products Industry Average Movement | 8.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: WALD's share price has been volatile over the past 3 months.
Volatility Over Time: WALD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 272 | Michel Brousset | www.waldencast.com |
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Waldencast plc Fundamentals Summary
| WALD fundamental statistics | |
|---|---|
| Market cap | US$654.74m |
| Earnings (TTM) | -US$113.13m |
| Revenue (TTM) | US$275.47m |
2.4x
P/S Ratio-5.8x
P/E RatioIs WALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WALD income statement (TTM) | |
|---|---|
| Revenue | US$275.47m |
| Cost of Revenue | US$132.68m |
| Gross Profit | US$142.79m |
| Other Expenses | US$255.92m |
| Earnings | -US$113.13m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 51.83% |
| Net Profit Margin | -41.07% |
| Debt/Equity Ratio | 27.4% |
How did WALD perform over the long term?
See historical performance and comparison